The Ministry of Health has announced a temporary disruption in the supply of the rotavirus vaccine, a critical component of the country’s routine immunisation programme for infants.
The rotavirus vaccine, administered orally, protects young children from severe diarrhoea, vomiting, and dehydration caused by the virus. Health Cabinet Secretary Aden Duale confirmed that the shortage affects the Rotavac Frozen vaccine, given to infants at six, ten, and fourteen weeks of age.
According to the ministry, the disruption is due to production delays at the manufacturer Bharat Biotech, following facility upgrades. The notification was issued by Gavi, the Vaccine Alliance, which oversees global vaccine distribution. These delays are expected to affect vaccine deliveries worldwide between 2026 and 2027.
As of March 3, 2026, Kenya had approximately 4,000 doses remaining nationally—enough for less than one month. A shipment originally expected in January 2026 has been postponed, with the next delivery now anticipated at the end of April.
The ministry is working closely with UNICEF and other partners to expedite shipments, redistribute available doses fairly across counties, and monitor stock levels to minimise disruption to routine immunisation services.
Parents and caregivers have been urged to continue taking their children for scheduled vaccinations, while also maintaining hygiene measures, including handwashing with soap, treating drinking water, proper food handling, and keeping household environments clean.
CS Duale reassured the public that restoring normal vaccine supply remains a top priority. “Protecting the health of all children remains our highest priority,” the ministry stated, emphasizing ongoing efforts with global partners to resolve the shortage.
